Loading clinical trials...

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation | Clinical Trials | Clareo Health

COMPLETEDNA

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation

Effective Public Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation: A Randomized Controlled Experiment

NCT05244356•Clinical Research Centre, Malaysia

View on ClinicalTrials.gov

Summary

This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to take up the COVID-19 vaccine, recommend the vaccine, and also willingness to propagate the exposed message.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Willing and able to give informed consent for participation in the trial
•Malaysian nationality.
•Can understand either the English or Malay language.
•Aged 18 years or above

Exclusion Criteria

•Received at least one COVID-19 vaccination dose

Locations (1)

Institute for Clinical Research, National Institutes of Health, Malaysia

Shah Alam, Selangor, Malaysia

Key Dates

Start Date

April 29, 2021

Primary Completion Date

June 7, 2021

Completion Date

June 7, 2021

Last Updated

February 17, 2022

Enrollment

5,784

ACTUAL participants

Conditions

COVID-19Respiratory DiseaseVaccine RefusalInfectious DiseaseCoronavirus InfectionsBehavior, HealthPneumoniaRespiratory Tract InfectionsLung DiseasesPneumonia, Viral

Interventions

Health message exposure

BEHAVIORAL

A New Portable Device for Non-invasive Ventilatory Support

NCT06716502

HealthyRespiratory Disease

View study

RECRUITINGPHASE1

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162

COVID-19

View study

RECRUITINGNA

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation

Inclusion Criteria

Exclusion Criteria

A New Portable Device for Non-invasive Ventilatory Support

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

Dime La VerDAD: Verify, Debunk, and Disseminate